Analysis Of D1-3n-butyphthalide On Treatment Of Somnipathy In Diqing Military Region And Balance Of Neorotransmitter

PurposeThe purpose of this thesis lies in analyzing the effect of Dl-3n-butyphthalide on treatment of somnipathy in Diqing Military Region, which is under the plateau hypoxia climate, and in influence on brain neurotransmitters.Methodsa. Diqing Military Region, at the attitude of3700m, was numbered by companies. Then, we draw4companies of them randomly, with random cluster sampling method. There were196armymen in the4groups.b. The questionnaires we used in the survey were PSQI, HAMD, HAMA, and those we made by ourselves. With the results of the survey, we brought in the targets with somnipathy, while bringing out the ones who suffered from somnipathy and depression/anxiety.(PSQI>7, and HAMA<8/HAMD≤8). There were36ones of the targets. We divided the targets in2groups with18subjects each. The experiment was conducted when randomized, double blinded and placebo-controlled. The treatment group took Dl-3n-butyphthalide orally, and the placebo group took simulation of the capsules orally. Both group took200mg at a time, and three times in one day. The course of the treatment was2weeks. We monitored the subjects with polysomnography/PSG and Encphalofluctuograph/EFG in the treatment course. And after the treatment, we conducted PSQI, HAMD and HAMA survey with the subjects.c. The varieties we recorded with PSG included recording time, sleep latency, number of wake after sleep onset/WASO, amount of awakening time, amount of sleeping time, sleep efficiency, sleep stage Ⅰ, Ⅱ, Ⅲ+Ⅳ, and REM period, number of transitions during sleep, average SaO2when awake, lowest SaO2during sleep, highest SaO2during sleep, average SaO2during sleep. And the varieties we recorded with EFG included Glu, GABA,5-HT, Ach, NE, DA, power of neurotransmitters, relative power of neurotransmitters, gross power, cerebral state index and entropy,d. We analyzed the data with the software of spss17.0. The data was included in x±s. T test was applied in the comparison among groups, and χ2was applied in the comparison of power. There is statistical significance when P<0.05.Resultsa. There were no significant difference of the baseline information between the2groups, including age, ethnic group, degree of education, results of HAMD, HAMA and PSQI. And so they were comparable.b. Before the treatment, results showed that there was statistic difference between the treatment and placebo groups only in the data of number of transitions during sleep, with no statistic difference in all the other data recorded with PSG.c. After14days of treatment, results showed that there were significant difference in the data of sleep latency, sleep stage Ⅲ+Ⅳ. average SaO2when awake and average SaO2during sleep. No statistic difference was shown in all the other data recorded with PSGd. Before the treatment, results showed that there was no significant difference between the2groups in all the varieties we recorded with EFG.e. After14days of treatment, results showed that there were significant difference in the data of5-HT, Ach, NE and gross power, No statistic difference was shown in all the other data recorded with EFG.f. In the course of treatment, there were4adverse events.2of them were in the placebo group, and the symptoms were diarrhea and nausea. The other2of them were in the plateau somnipathy group, and the symptoms were nausea and xerostomia. It might be associated with the capsules they took. No pertinent treatment was conducted in all the4cases. And yet in the follow-up visit, they recovered well.Conclusionsa. Dl-3n-butyphthalide is able to improve of sleep quality of those who suffer from plateau somnipathy. It mainly shows in sleep latency, sleep stage Ⅲ+Ⅳ, average SaO2when awake and average SaO2during sleep. The results suggest that D1-3n-butyphthalide has therapeutic significance in treating plateau somnipathy. It provides reliable clinical basis for Dl-3n-butyphthalide in early intervention of research and treatment of plateau somnipathy.b. Dl-3n-butyphthalide is able to significantly improve the power of5-HT, Ach, NE of the patients who suffere from plateau somnipathy.c. There were no significant adverse drug reactions when Dl-3n-butyphthalide was used in treating those who suffered from plateau somnipathy. It’s safe and effective.